Actavia Life Sciences, Inc. Stock

RASP

US7538881068

Biotechnology & Medical Research

Market Closed - OTC Markets 09:49:06 2024-06-03 EDT			5-day change	1st Jan Change
0.0140 ^USD	-2.78%		+2,700.00%	+2,700.00%

24-05-20	Actavia Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
24-02-16	Actavia Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Valuation: Actavia Life Sciences, Inc.

Market Cap	3.09M 2.71M 2.56M 2.33M 4.36M 296M 4.4M 30.62M 11.86M 151M 11.59M 11.34M 486M	P/E 2022	-1.98x	P/E 2023	-2x
Enterprise Value	3.22M 2.83M 2.67M 2.43M 4.56M 309M 4.59M 31.97M 12.38M 158M 12.1M 11.84M 507M	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	14.81%	Yield 2022 *	-	Yield 2023	-

* Estimated data More valuation ratios

Latest news: Actavia Life Sciences, Inc.

24-05-20	Actavia Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
24-02-16	Actavia Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
24-01-05	Actavia Life Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	CI
24-01-04	Actavia Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt	CI
23-08-14	Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	CI
23-05-15	Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	CI
23-03-02	Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	CI
23-02-09	Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	CI
23-02-08	Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
22-08-22	Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	CI
22-06-21	Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	CI
22-06-16	Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	CI
22-06-09	Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

More news

Press Releases: Actavia Life Sciences, Inc.

24-04-10	Actavia Life Sciences : Change in Certifying Accountants - Form 8-K	PU
23-03-02	RASNA THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
23-02-09	RASNA THERAPEUTICS INC. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
23-01-23	Rasna Therapeutics : Certificate of Incorporation/Bylaws - Form 8-K	PU
23-01-23	RASNA THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

Managers and Directors: Actavia Life Sciences, Inc.

Manager	Title	Age	Since
Keeren Shah DFI	Director of Finance/CFO	50	2020-07-30
Jules S. Jacob PRN	Corporate Officer/Principal	-	2017-06-30

Director	Title	Age	Since
John Brancaccio BRD	Director/Board Member	78	2016-07-31
Willy Simon CHM	Chairman	74	2020-10-13
Gary Jacob BRD	Director/Board Member	79	2020-12-22

More insiders

Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
RASP Stock

The best tools reserved for subscribers to boost the performance of your investments!

1 year	0		0.01
3 years	0		0.04
5 years	0		0.06
10 years	0		10

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTAVIA LIFE SCIENCES, INC.	-2.78%	+2,700.00%	+40.00%	-30.00%	386K
WUXI APPTEC CO., LTD.	-3.30%	+1.50%	+57.79%	+99.14%	72.26B
ARGENX SE	+1.25%	-3.01%	+37.83%	+87.66%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+2.12%	+5.26%	+35.69%	+23.40%	27.73B
INSMED INCORPORATED	-3.06%	-1.81%	-14.01%	+357.24%	25.73B
BIONTECH SE	-0.75%	+2.56%	+0.45%	-3.28%	24.75B
GENMAB A/S	+0.40%	+0.75%	+23.72%	-11.33%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	-2.12%	+150.24%	+326.97%	15.06B
EXELIXIS, INC.	+0.36%	-0.34%	+48.98%	+167.40%	14.41B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.21%	+1.17%	-3.95%	+512.06%	14.23B
Average	-0.72%	+0.40%	+37.67%	+152.93%	27.52B
Weighted average by Cap.	-0.77%	+0.31%	+38.16%	+132.99%

	2022	2023
Net sales	-	-
Net income	-687K -602K -569K -519K -971K -65.81M -978K -6.81M -2.64M -33.62M -2.58M -2.52M -108M	-4.44M -3.9M -3.68M -3.36M -6.28M -426M -6.33M -44.06M -17.06M -218M -16.68M -16.32M -699M
Net Debt	180K 158K 149K 136K 255K 17.28M 257K 1.79M 693K 8.83M 677K 662K 28.38M	136K 119K 113K 103K 192K 13.03M 194K 1.35M 522K 6.66M 511K 500K 21.4M

Actavia Life Sciences, Inc. Stock

Stocks

RASP

US7538881068

Biotechnology & Medical Research

Valuation: Actavia Life Sciences, Inc.

Latest news: Actavia Life Sciences, Inc.

Press Releases: Actavia Life Sciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Actavia Life Sciences, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

1 day	-2.78%
1 week	+2,700.00%
Current month	+2,700.00%
1 month	+2,700.00%
3 months	+2,700.00%
6 months	+2,700.00%
Current year	+2,700.00%